Xspray Pharma AB (publ) (FRA:6XP)

Market Cap	64.54M -40.5%
Revenue (ttm)	224.74K
Net Income	-14.99M
EPS	-0.38
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.400
Previous Close	1.412
Day's Range	1.264 - 1.462
52-Week Range	1.238 - 5.490
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partn...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6XP

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error